Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 2.03B | 2.07B | 1.70B | 1.31B | 1.10B | 904.40M |
Gross Profit | 1.55B | 1.45B | 1.16B | 805.60M | 752.10M | 582.30M |
EBITDA | 428.10M | 423.70M | 323.60M | 109.50M | 139.60M | 110.30M |
Net Income | 402.20M | 418.30M | 206.30M | 4.60M | 16.80M | 6.80M |
Balance Sheet | ||||||
Total Assets | 3.52B | 3.09B | 2.59B | 2.25B | 2.05B | 1.87B |
Cash, Cash Equivalents and Short-Term Investments | 1.28B | 953.40M | 704.20M | 674.70M | 791.60M | 947.60M |
Total Debt | 83.10M | 1.39B | 1.42B | 1.40B | 1.25B | 1.04B |
Total Liabilities | 2.19B | 1.88B | 1.86B | 1.77B | 1.49B | 1.27B |
Stockholders Equity | 1.33B | 1.21B | 732.70M | 476.40M | 556.30M | 603.60M |
Cash Flow | ||||||
Free Cash Flow | 290.90M | 305.40M | 36.50M | -38.30M | -190.80M | -82.50M |
Operating Cash Flow | 406.50M | 430.30M | 145.70M | 119.00M | -68.10M | 84.00M |
Investing Cash Flow | -137.90M | -146.20M | -119.40M | -191.10M | -82.70M | 14.00M |
Financing Cash Flow | 263.80M | -28.10M | -13.60M | -40.30M | 40.70M | 605.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $13.32B | 32.02 | 7.82% | 3.06% | 4.58% | 55.99% | |
80 Outperform | $23.49B | 37.63 | 9.46% | 0.95% | 0.32% | 64.36% | |
78 Outperform | $33.85B | 65.53 | 23.72% | ― | 9.11% | -17.87% | |
76 Outperform | $21.11B | 53.99 | 37.92% | ― | 23.49% | 71.25% | |
51 Neutral | $7.55B | 0.39 | -61.90% | 2.32% | 17.14% | 1.55% | |
51 Neutral | $23.24B | ― | -7.10% | 3.69% | -0.76% | -55.03% | |
50 Neutral | $1.26B | ― | -92.31% | ― | 27.65% | -28.22% |
On June 6, 2025, Insulet Corporation amended its Credit Agreement to refinance $481.25 million in term loans, reducing the interest rate margin and maintaining similar terms to the previous loans. Additionally, Insulet issued a redemption notice on June 9, 2025, for its outstanding Convertible Senior Notes due 2026, with plans to redeem them by August 20, 2025, potentially impacting stock transactions as hedge positions are unwound.
The most recent analyst rating on (PODD) stock is a Buy with a $380.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.
Insulet Corporation held its 2025 Annual Meeting of Stockholders on May 22, 2025, where shareholders elected three Class III directors, approved executive compensation, and ratified the appointment of Grant Thornton LLP as the independent public accounting firm for the fiscal year ending December 31, 2025. Additionally, the Insulet Corporation 2025 Stock Option and Incentive Plan was approved, indicating continued shareholder support for the company’s strategic initiatives and governance practices.
The most recent analyst rating on (PODD) stock is a Hold with a $185.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.
On April 28, 2025, Insulet Corporation announced the appointment of Ashley McEvoy as President and CEO, succeeding Jim Hollingshead. This leadership change is expected to further the company’s success, as McEvoy brings extensive experience in healthcare leadership and innovation. Under Hollingshead’s tenure, Insulet achieved market leadership in diabetes care with the launch of the Omnipod 5. The company also announced it expects to exceed its first-quarter revenue guidance and plans to raise its full-year 2025 guidance, indicating strong financial performance and growth potential. The planned Investor Day has been postponed due to the CEO transition.